Mocetinostat (MGCD0103)

Name: Mocetinostat (MGCD0103)
Brand: Selleck Chemicals
SKU: S1122
Rating: 5 (90 reviews)

For research use only.

Catalog No.S1122 Synonyms: MG0103

90 publications

Mocetinostat (MGCD0103) Chemical Structure

CAS No. 726169-73-9

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Selleck's Mocetinostat (MGCD0103) has been cited by 90 publications

Cancer Cell, 2021, S1535-6108(20)30662-0

PubMed: 33482121 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5056

PubMed: 34417458 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3862

PubMed: 34359763 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):333

PubMed: 34482361 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Sci Rep, 2020, 10(1):4337

PubMed: 32152395 ( click the link to review the publication )

Front Genet, 2020, 11:80

PubMed: 32158467 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:752

PubMed: 32850856 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:4705615

PubMed: 32775424 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )

J Cancer, 2020, 11(7):1915-1926

PubMed: 32194803 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Oncol, 2019, 13(9):1944-1958

PubMed: 31225930 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

J Mol Cell Cardiol, 2017, 112:74-82

PubMed: 28886967 ( click the link to review the publication )

Biotechnol Bioeng, 2017, 114(11):2660-2667

PubMed: 28667749 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

Pain Physician, 2017, 20(5):E673-E685

PubMed: 28727712 ( click the link to review the publication )

Theriogenology, 2017, 87:298-305

PubMed: 27742403 ( click the link to review the publication )

Circ J, 2017, 82(1):192-202

PubMed: 28747611 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6319-6329

PubMed: 28030834 ( click the link to review the publication )

Cell Death Discov, 2016, 2:16036

PubMed: 27551526 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

J Lipid Res, 2016, 57(5):868-81

PubMed: 27013100 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(22):2838-2854

PubMed: 27573019 ( click the link to review the publication )

Future Med Chem, 2016, 8(13):1553-71

PubMed: 26971619 ( click the link to review the publication )

Cell Signal, 2016, 28(8):1015-24

PubMed: 27185186 ( click the link to review the publication )
Hypertens Res, 2016, 39(10):709-716

PubMed: 27278287 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Nucleic Acids Res, 2015, 10.1093/nar/gkv188

PubMed: 25769527 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(24):20449-65

PubMed: 26036259 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Blood, 2014, 123(10):1535-43

PubMed: 24449212 ( click the link to review the publication )

J Heart Lung Transplant, 2014, 33(6):644-53

PubMed: 24746638 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

J Neurosci, 2014, 34(17):6112-22

PubMed: 24760871 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1491

PubMed: 25341045 ( click the link to review the publication )

BMC Biol, 2014, 12:95

PubMed: 25406762 ( click the link to review the publication )

BMC Biol, 2014, 10.1186/1741-7007-12-30

PubMed: 24779377 ( click the link to review the publication )

Oncogenesis, 2014, 3:e127

PubMed: 25402609 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-17

PubMed: 24200994 ( click the link to review the publication )

Cell Signal, 2014, 26(12):2912-20

PubMed: 25220405 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Fibrogenesis Tissue Repair, 2014, 7:10

PubMed: 25024745 ( click the link to review the publication )
Mol Cell, 2013, 52(3):406-20

PubMed: 24120667 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Oncogene, 2013, 33(5):653-64

PubMed: 23524580 ( click the link to review the publication )

J Neurosci, 2013, 33(17):7535-47

PubMed: 23616558 ( click the link to review the publication )

Pain, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

J Dent Res, 2013, 93(2):148-54

PubMed: 24334408 ( click the link to review the publication )

Mol Pharm, 2013, 10(1):307-18

PubMed: 23186311 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(5):e000317

PubMed: 24088507 ( click the link to review the publication )

Melanoma Res, 2013, 23(5):341-8

PubMed: 23963286 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Oncogene, 2012, 32(33):3896-903

PubMed: 22945647 ( click the link to review the publication )

Biochem J, 2012, 447(3):457-64

PubMed: 22908849 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52095

PubMed: 23251689 ( click the link to review the publication )

Oncogene, 2011, 30(27):3062-72

PubMed: 21577204 ( click the link to review the publication )

J Biol Chem, 2011, 286(27):23842-51

PubMed: 21489983 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)	HDAC11 ^[1] (Cell-free assay)	HDAC3 ^[1] (Cell-free assay)
0.15 μM	0.29 μM	0.59 μM	1.66 μM

In vitro

MGCD0103 inhibits only a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11 at nanomolar or low micromolar concentrations, in a dose-dependent manner. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The exocyclic amino group in MGCD0103 is necessary for enzyme inhibitory activity because HDAC-inhibitory activity against HDAC1 and HDAC2 is completely abolished with the desamino analogue. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells whereas NVP-LAQ824 inhibits almost 100% of that in these cells. In A549 cells, MGCD0103 also exhibits dose-dependent inhibition of HDAC activity in whole cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PBMC	MX;BdI9xfG:\|aYOgRZN{[Xl?	NUf6cFBjOC53L{KvN{DPxE1?	M4i5N\|I1NzR6IHi=		M{HFcolv\HWlZYOgZZBweHSxc3nzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	NILWU489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOlk1Pyd-MkC0NFY6PDd:L3G+
HeLa	NHTsVXJHfW6ldHnvckBCe3OjeR?=	Mne4NVAh\|ryPwrC=	NUju[YlWPyCq	NETVNZRFVVOR	MoK1[Il{enWydIOgco9zdWGuIIPwbY5ldGViY3jlZ4txd2mwdDDmeY5kfGmxbh?=	NHnxVXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWzPFg1OCd-MkC1N\|g5PDB:L3G+
HeLa	M3;QVWZ2dmO2aX;uJGF{e2G7	Ml3HNVAh\|ryPwrC=	Ml\vOk8yOi9{NDDo	NUjpdIpXTE2VTx?=	NHT5b5pqdmS3Y3XzJI1qfG:2aXOgZYNkfW23bHH0bY9vKGGwZDDk[YxigWWmIICyNUBmgHC{ZYPzbY9v	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV\|OEi0NEc,OjB3M{i4OFA9N2F-
HeLa	NF7VdnZHfW6ldHnvckBCe3OjeR?=	MorwNE4{NTFyIN88US=>	MYW4JIg>	NYTLTY14TE2VTx?=	M4rKdYlv[3KnYYPld{Bk[XOyYYPlJFMh[W6mIEegZYN1cX[jdHnvckBld3OnIHTldIVv\GWwdHz5	M4DSPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUO4PFQxLz5{MEWzPFg1ODxxYU6=
HeLa	M4XWZmZ2dmO2aX;uJGF{e2G7	NFTkd5kxNjNvMUCg{txO	NITBclA5KGh?	NWPufJE1TE2VTx?=	MlK2bY5kemWjc3XzJIFk\XS7bHH0[YQhUDNiS{mgLGg{UzmDYzmgZZQhOTBizszN	NXe0NXJSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1N\|g5PDBpPkKwOVM5QDRyPD;hQi=>
DMS114	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DKPWlEPTB;NkSwJI5O	MkK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OEK2OFMoRjJyNkiyOlQ{RC:jPh?=
H82	NG\ibIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3G4eWlEPTB;MkWwJI5O	M3rOVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkiyOlQ{Lz5{ME[4NlY1OzxxYU6=
H146	NWm4T4djT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2C4SGlEPTB;M{Wgcm0>	MkD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OEK2OFMoRjJyNkiyOlQ{RC:jPh?=
H526	MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHxTWM2OD12OECgcm0>	NHnsTXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4NlY1Oyd-MkC2PFI3PDN:L3G+
KM-H2	NU[5Oo9XTnWwY4Tpc44hSXO\|YYm=	MoTENeKh\|ryP	NUfobo1vOC5{NT20PEBp	M4HZNWROW09?	MWDhZ5RqfmG2ZYOgUmYuc0J?	NXKxV5N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
L428	NY\YWIVMTnWwY4Tpc44hSXO\|YYm=	NWTmU5NoOcLizszN	NEjySGoxNjJ3LUS4JIg>	MmLBSG1UVw>?	NGHrWldi[3SrdnH0[ZMhVkZva1K=	NUm3cYoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
HD-LM2	MV\GeY5kfGmxbjDBd5NigQ>?	MoHGNeKh\|ryP	NELzeIgxNjJ3LUS4JIg>	M1TDemROW09?	M1zieIFkfGm4YYTld{BPTi2tQh?=	NUS0e29HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
KM-H2	MV7GeY5kfGmxbjDBd5NigQ>?	NXLmSoNnOC53L{Gg{txO	MX6yOE81QCCq	MV3EUXNQ	Mn\qeZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	MkDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
L428	NGj2WW5HfW6ldHnvckBCe3OjeR?=	NXOz[WE4OC53L{Gg{txO	M4DXT\|I1NzR6IHi=	M4jGdGROW09?	MmDkeZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	NY\oW4ZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
HD-LM2	MX7GeY5kfGmxbjDBd5NigQ>?	NUHsbFdMOC53L{Gg{txO	MmfXNlQwPDhiaB?=	MnjESG1UVw>?	M1HNbpVxemWpdXzheIV{KFSQRj5OtUBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5	NGLPVlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
KM-H2	M4f3ZmZ2dmO2aX;uJGF{e2G7	NFzyN2EyyqEQvF2=	Mk\LNlQwPDhiaB?=	M4L5bGROW09?	NEHWVoZld3ewcnXneYxifGW\|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{	Mn;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
L428	MkS1SpVv[3Srb36gRZN{[Xl?	M{\yRVHDqM7:TR?=	Mn\vNlQwPDhiaB?=	MXnEUXNQ	NYX6Slds\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>?	NXHS[IVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
HD-LM2	M3nYV2Z2dmO2aX;uJGF{e2G7	MmfPNeKh\|ryP	NE\ke4szPC92ODDo	NV\EWmlRTE2VTx?=	NGmxbWtld3ewcnXneYxifGW\|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{	MkXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
KM-H2	M2OzOWFxd3C2b4Ppd{BCe3OjeR?=	NHyyW\|cxNjFxMD61M\|Eh\|ryP	NHvXbG81QCCq	NGrSWWlFVVOR	M3\YVYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
L428	MVLBdI9xfG:\|aYOgRZN{[Xl?	NFPxZ\|IxNjFxMD61M\|Eh\|ryP	NF\pcZI1QCCq	Mn\NSG1UVw>?	NFPWe2tqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	M2PCR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
HD-LM2	MVjBdI9xfG:\|aYOgRZN{[Xl?	M4TaVVAvOS9yLkWvNUDPxE1?	NEP6V2E1QCCq	MlTRSG1UVw>?	MV\pcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NVu0[XNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
KM-H2	NFLabHNHfW6ldHnvckBCe3OjeR?=	NWD6O2pDOC5zLUKg{txO	MYqyOEBpyqB?	Mme2SG1UVw>?	NIG4NGx{cG:5czDhZ4V1gWyjdHnvckBw\iCqaYP0c45mKDNiYX7kJJVxemWpdXzheIlwdiCxZjD0bIUh[2WubDDjfYNt\SC{ZXf1cIF1d3K7IIDyc5RmcW5icEKx	Ml7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
L428	MmnaSpVv[3Srb36gRZN{[Xl?	NULxO45bOC5zLUKg{txO	MYGyOEBpyqB?	MWPEUXNQ	NGPwPZd{cG:5czDhZ4V1gWyjdHnvckBw\iCqaYP0c45mKDNiYX7kJJVxemWpdXzheIlwdiCxZjD0bIUh[2WubDDjfYNt\SC{ZXf1cIF1d3K7IIDyc5RmcW5icEKx	M2n2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
HD-LM2	MV;GeY5kfGmxbjDBd5NigQ>?	M4DDWVAvOS1{IN88US=>	MlrtNlQhcMLi	M1HTZ2ROW09?	Mo\Ud4hwf3NiYXPleJlt[XSrb36gc4YhcGm\|dH;u[UA{KGGwZDD1dJJm\3WuYYTpc44hd2ZidHjlJINmdGxiY4njcIUhemWpdXzheI9zgSCycn;0[YlvKHB{MR?=	M3XMVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
KM-H2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NU[1XXF6PzMEoHi=	MkDMSG1UVw>?	MmG5TWM2OD1{Lki2JO69VQ>?	NWX2TmxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
L428	NWXFOGlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXvxTVNPPzMEoHi=	MXzEUXNQ	MVrJR\|UxRTFwOU[g{txO	NUTjfJQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
HD-LM2	NIGxWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUO3NuKhcA>?	Mkf2SG1UVw>?	NGPTV41KSzVyPUGuPFgh\|ryP	NHPoRYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
LP1	NW\0WVRbTnWwY4Tpc44hSXO\|YYm=	NEGxPYoyyqEQvF2=	MofCNlQhcA>?		MV\lcohidmOnczC1MWFENWmwZIXj[YQhVUGJRT3BN{Bo\W6nIHX4dJJme3Orb36=	M{\CNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUexPFIyLz5{MUG3NVgzOTxxYU6=
ANBL6	M2XZVWZ2dmO2aX;uJGF{e2G7	NFnnc4wyyqEQvF2=	NEnBNnEzPCCq		M1\jUoVvcGGwY3XzJFUuSUNvaX7keYNm\CCPQVfFMWE{KGenbnWg[ZhxemW\|c3nvci=>	Moi5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{G4NlEoRjJzMUexPFIyRC:jPh?=
HMEC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTF7IN88US=>	NGLCd2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxO\|Q2PSd-MkGzNVc1PTV:L3G+
SW620	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDZO49GUUN3ME2xJO69VQ>?	MmrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUe0OVUoRjJzM{G3OFU2RC:jPh?=
SW48	NEK5PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIThSnhKSzVyPUCuPEDPxE1?	NI\zOGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxO\|Q2PSd-MkGzNVc1PTV:L3G+
HT-29	NHq1U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTBwNzFOwG0>	NIm0T3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxO\|Q2PSd-MkGzNVc1PTV:L3G+
HCT15	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jn[GlEPTB;MD63JO69VQ>?	Mmm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUe0OVUoRjJzM{G3OFU2RC:jPh?=
PAXF 1657L†	NV7IS\|FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfDdHhrTUN3ME2wMlMh\|ryP	MlvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|N{W2O\|koRjJzM{e1Olc6RC:jPh?=
PAXF 546L†	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fpWGVEPTB;MT61JO69VQ>?	M1;wO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{e1Olc6Lz5{MUO3OVY4QTxxYU6=
Panc-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PHZmVEPTB;MT64JO69VQ>?	NH;Pcoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3OVY4QSd-MkGzO\|U3Pzl:L3G+
MiaPaca-2	NVH2fY9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEe5d2RGSzVyPUCuOkDPxE1?	NWHBTHVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|U3PzlpPkKxN\|c2Pjd7PD;hQi=>
AsPC-1	M1\oSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvFR\|UxRTNwOTFOwG0>	NHuyOnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3OVY4QSd-MkGzO\|U3Pzl:L3G+
BxPC-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjFR\|UxRTFwMTFOwG0>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5NU[3PUc,OjF\|N{W2O\|k9N2F-
MMCs	MVPGeY5kfGmxbjDBd5NigQ>?	NGfrSW4yyqEQvF2=	M4TDSlYuOjRiaB?=		NHX0OG5ld3OnLXTldIVv\GWwdHz5JIlvcGmkaYTzJJRp\SC2cnnt[ZRpgWyjdHnvckBt\X[nbDDv[kBJOy2NOTCoTFMuUzmvZUOp	M3XzZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxN\|c5Lz5{NES1NVM4QDxxYU6=
MMCs	NF7TcVVHfW6ldHnvckBCe3OjeR?=	M2PDXFHDqM7:TR?=	MYqyOEBp		M3nTN4F2\22nboTzJIdtd2KjbDDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhcGm\|dH;u[UBJOy2NOT:xOEApUDNvS{mvNVRi[yliYX7kJGg1NUtzMjCoTFQuUzF{YXOp	M2nKbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxN\|c5Lz5{NES1NVM4QDxxYU6=
MMCs	M1TkU2Z2dmO2aX;uJGF{e2G7	NIfwVXMyyqEQvF2=	MmLPNlQhcA>?		MYPpcoNz\WG\|ZYOgTGFVKGGldHn2bZR6	NVzOcmVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVE{PzhpPkK0OFUyOzd6PD;hQi=>
MMCs	MWjGeY5kfGmxbjDBd5NigQ>?	NIPs[JIxNjVxMTFOwG0>	NEjyVlIzPCCq		M3PKWZNpd3e\|IES1MYZwdGRic4TpcZVt[XSrb36gbY4h[0ePUDDs[ZZmdHN?	MoXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NUGzO\|goRjJ2NEWxN\|c5RC:jPh?=
MMCs	MV3GeY5kfGmxbjDBd5NigQ>?	MkT6NUDPxG1?	M1\w[lAuPDhiaB?=		M1jNTIlv[3KnYYPld{BPWFKDIIDyc5RmcW5iZYjwdoV{e2mxbtMgNk446oDVMz61JIZwdGR?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3MUO3PEc,OjR2NUGzO\|g9N2F-
Panc1	MnG5R4VtdCCYaXHibYxqfHliQYPzZZk>	NU\B[2Z5OcLizszN	NFWzPW04OsLiaB?=	MVnEUXNQ	M2LpbYVvcGGwY3XzJIdmdWOrdHHibY5mNWmwZIXj[ZMh[2WubDD2bYFjcWyrdImg[IVkemWjc3W=	NHmxbXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3Nlk1OSd-MkW4O\|I6PDF:L3G+
Panc1	NH\FfmlCeG:ydH;zbZMhSXO\|YYm=	NGjueGwyyqEQvF2=	M1LhXFczyqCq	NWDLSFJQTE2VTx?=	MVzz[Y5{cXSrenXzJHBidmNzIHPlcIx{KG[xcjDn[Y1kcXSjYnnu[U1qdmS3Y3XkJIFxd3C2b4Ppdy=>	NWn6bY1VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|I6PDFpPkK1PFczQTRzPD;hQi=>
Panc1	NWTIbI5nTnWwY4Tpc44hSXO\|YYm=	Mly4NE42NzFxMj61JO69VQ>?	M1TUPVQ5KGh?	MYXEUXNQ	MmX4doVlfWOnczDlfJBz\XO\|aX;uJI9nKFqHQkGgc44h[m:2aDDtVm5CKGGwZDDwdo91\WmwIHzleoVtyqB?	NWPuO3BERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|I6PDFpPkK1PFczQTRzPD;hQi=>
Panc1	MWjGeY5kfGmxbjDBd5NigQ>?	Mnf4NE42NzFxMj61JO69VQ>?	MoTNOFghcA>?	NGPsO3lFVVOR	M2TrS5VxemWpdXzheIV{KG2rUj2yNFM>	MlXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{K5OFEoRjJ3OEeyPVQyRC:jPh?=
MOLP8	M4TlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXTEc5R5PDhiaB?=		MmOxTWM2OD1yLkdCtUAxNjB2zszN	NVPBdG15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVE2OThpPkK2NFkyPTF6PD;hQi=>
T47D	NVzY[YxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2nDWFQ5KGh?		MUXJR\|UxRTFwMUeg{txO	M{nQVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{e4NFM5Lz5{NkO3PFA{QDxxYU6=
MCF7	M364dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXq0PEBp		M3;rU2lEPTB;MD62O{DPxE1?	NX3aV2NIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO\|gxOzhpPkK2N\|c5ODN6PD;hQi=>
BT549	NGnNWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXG0PEBp		M4f0XmlEPTB;ND6zPEDPxE1?	NFTCcYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO3PFA{QCd-Mk[zO\|gxOzh:L3G+
MDA-MB-231	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHXhbZA1QCCq		MmWxTWM2OD1\|LkC0JO69VQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN5OECzPEc,OjZ\|N{iwN\|g9N2F-
HEK293	MnnNSpVv[3Srb36gZZN{[Xl?				MVXJcohq[mm2aX;uJI9nKEiGQVOxJIlvKEiHS{K5N{Bk\WyuczygTWM2OD1yLkGz{txO	NH\td4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOwPFU3Oyd-MUizNFg2PjN:L3G+
HEK293	M3PT[GZ2dmO2aX;uJIF{e2G7				MYHJcohq[mm2aX;uJI9nKEiGQVOzJIlvKEiHS{K5N{Bk\WyuczygTWM2OD1yLk[x{txO	M{nTS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{C4OVY{Lz5zOEOwPFU3OzxxYU6=
HCT116	M2nPSWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NV[4VJE3PzJiaILz		NHPvNXNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNlnPxE1?	NV3U[nVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|A{PjZpPkG4OVcxOzZ4PD;hQi=>
HCT116	MYPGeY5kfGmxbjDhd5NigQ>?				NFTIdmhKdmS3Y4Tpc44hd2ZicEKxZ4lxN3ejZkGgdJJwfGWrbjDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyC{ZXzheIl3\SC2bzDNV\|I4PSxiRVO1NF0xNjR3zszN	NYntOVRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|A{PjZpPkG4OVcxOzZ4PD;hQi=>
Du145	NEXaUYRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXTnfHI4PzJiaILz		NFnoeYdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFT1NVQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD62O:69VQ>?	M{npNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUewN\|Y3Lz5zOEW3NFM3PjxxYU6=
A549	NXH1Snk6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2LWOFczKGi{cx?=		NEjnV29CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkpOwG0>	MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{CzOlYoRjF6NUewN\|Y3RC:jPh?=
HCT116	Mlf0R4VtdCCleXPs[UBie3OjeR?=				MYrD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2VuIFXDOVA9Oc7:TR?=	M{HDNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUewN\|Y3Lz5zOEW3NFM3PjxxYU6=
T24	M2PCVmZ2dmO2aX;uJIF{e2G7				M33wVGlv\HWldHnvckBw\iCKMzDobZN1d26nIHHj[ZR6dGG2aX;uJIlvKGi3bXHuJHQzPCClZXzsd{Bz\WyjdHn2[UB1dyCPU{K3OUwhTUN3ME2xMlM5\|ryP	NWq0V3puRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|A{PjZpPkG4OVcxOzZ4PD;hQi=>
HCT116	NIfCZ\|BCeG:ydH;zbZMh[XO\|YYm=	M1jJUFEhfU1?			NH3jN5JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJGhEXDFzNjDj[YxteyCjdDCxJJVO	MnjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{CzOlYoRjF6NUewN\|Y3RC:jPh?=
HCT116	Ml\ORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				M3HPcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjQQvF2=	NFPiN5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFMxPCd-MUmxNVQ{ODR:L3G+
HCT116	M3nPZWZ2dmO2aX;uJIF{e2G7		MX[xOkBpenN?		Ml:5TY5lfWO2aX;uJI9nKHB{MWfBSlEwS0mSMTDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczD0eYJ2dGmwIHzleoVtKGGodHXyJFE3KGi{czDifUBtfWOrZnXyZZNmKGG\|c3H5MEBGSzVyPUCuOu69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNEOwOEc,OTlzMUSzNFQ9N2F-
T24	NYSyRlhiTnWwY4Tpc44h[XO\|YYm=		MlmzNVYhcHK\|		MmHJTY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdiCrbjDoeY1idiCWMkSgZ4VtdHNiYX\0[ZIhOTZiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nMEBGSzVyPEJOwG0>	M1r0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0N\|A1Lz5zOUGxOFMxPDxxYU6=
HCT116	M1m1b2FvfGmycn;sbYZmemG2aY\lJIF{e2G7				MnXtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44tKEmFNUC9NE4{Oc7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ3MEKyNUc,OjF4NUCyNlE9N2F-
H1299	NGjmVGpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				NH;2SnVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFixNlk6KGOnbHzzMEBKSzVyPUGuOFTPxE1?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ3MEKyNUc,OjF4NUCyNlE9N2F-
HCT116	M1LWbWFvfGmycn;sbYZmemG2aY\lJIF{e2G7				NG\wUXZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{whUUN3ME2wMlMy\|ryP	M33NXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{SyOFk3Lz5{MUe0NlQ6PjxxYU6=
Sf9	NFv3OXdHfW6ldHnvckBie3OjeR?=		MoG0NkBpenN?		NWPnTlVCUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIlv[3WkYYTl[EBnd3JiMjDodpMhfXOrbnegVmhMUy2DYzDmcJVwem:pZX7pZ{B{fWK\|dILheIUtKEmFNUC9NE4yODMQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzByOUKwN{c,OjNyMEmyNFM9N2F-
HCT116	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=		MYK3NkBpenN?		M1u5cmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOzJ5zszN	NW\vc5VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNFY5PjdpPkKzNlA3QDZ5PD;hQi=>
A549	MoTtR5l1d3SxeHnjbZR6KGG\|c3H5		M4rn[\|czKGi{cx?=		NYPXbnBHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvOjd7zszN	MlX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{ME[4OlcoRjJ\|MkC2PFY4RC:jPh?=
MCF7	MlHoR5l1d3SxeHnjbZR6KGG\|c3H5		M{LJT\|czKGi{cx?=		NVT5RpJyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQvQDB5zszN	NGnqXlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KwOlg3Pyd-MkOyNFY5Pjd:L3G+
HCT116	M{\v[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		MnO2O\|IhcHK\|		NWfrdo1wS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIJ6KG2nYYP1dolv\yClZXzseYxieiCDVGCgcIV3\WxiYX\0[ZIhPzJiaILzJIJ6KGOnbHyteIl1\XJiZ3zvJIF{e2G7LDDJR\|UxRTBwN988US=>	MmjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
MCF7	Ml7MR5l1d3SxeHnjbZR6KGG\|c3H5		MkmzO\|IhcHK\|		Mn\LR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTDt[YF{fXKrbnegZ4VtdHWuYYKgRXRRKGyndnXsJIFnfGW{IEeyJIhzeyCkeTDj[YxtNXSrdHXyJIdtdyCjc4PhfUwhUUN3ME2xMlI3\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{OUS4N{c,OjN6Mkm0PFM9N2F-
A549	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=		MkXPO\|IhcHK\|		Ml21R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTDt[YF{fXKrbnegZ4VtdHWuYYKgRXRRKGyndnXsJIFnfGW{IEeyJIhzeyCkeTDj[YxtNXSrdHXyJIdtdyCjc4PhfUwhUUN3ME2xMlc{\|ryP	MoPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
DU145	Ml7ER5l1d3SxeHnjbZR6KGG\|c3H5		MlrZO\|IhcHK\|		MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTDt[YF{fXKrbnegZ4VtdHWuYYKgRXRRKGyndnXsJIFnfGW{IEeyJIhzeyCkeTDj[YxtNXSrdHXyJIdtdyCjc4PhfUwhUUN3ME2yMlA3\|ryP	M1\I[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5OFg{Lz5{M{iyPVQ5OzxxYU6=
Jurkat	NIfZcHBCeG:ydH;zbZMh[XO\|YYm=	MWKxJJRwKDFyIIXN	NIq0W5IzPCCqcoO=		NIfJdJhKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFr1dotifCClZXzsd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidH:gNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NHHoUo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVQ5Oyd-MkO4Nlk1QDN:L3G+
HeLa	M2\GZ2Z2dmO2aX;uJIF{e2G7	MnnlNUB1dyBzMDD1US=>	MnL1NlQhcHK\|		MVLJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDIN2s6SWNibHX2[Ywh[XRiMTD0c{AyOCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MoH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
Jurkat	Ml7qSpVv[3Srb36gZZN{[Xl?	MUixJJRwKDFyIIXN	M1fYc\|I1KGi{cx?=		NYnSc5NuUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEq3cnvheEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCKM1u5RYMhdGW4ZXygZZQhOSC2bzCxNEB2VSCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NF3jPJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVQ5Oyd-MkO4Nlk1QDN:L3G+
High5	NFzldJFHfW6ldHnvckBie3OjeR?=		NF;kPWY{KHSxIEK0JIhzew>?		M4fofGlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Eh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDobYdpPSClZXzsd{B2e2mwZzDBZ{1NgXNvVInyMWx6eyBqZYDzbYxwdi2jY3X0fYwqNUGPQzDhd{B{fWK\|dILheIUh[W[2ZYKgN{B1dyB{NDDodpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxRTBwOUZOwG0>	M1:xV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEm1NFE5Lz5{NEC5OVAyQDxxYU6=
HCT116	MkPIRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn3vO\|IhcHK\|		NGXOfJNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUGuOVfPxE1?	Ml\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUWwNVgoRjJ2MEm1NFE5RC:jPh?=
A549	NF\zdW9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUDBNWVCPzJiaILz		M4T3eGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTFwNkZOwG0>	MknIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUWwNVgoRjJ2MEm1NFE5RC:jPh?=
High5	MkjxSpVv[3Srb36gZZN{[Xl?		MXGzJJRwKDJ2IHjydy=>		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOzJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiaHnnbFUh[2WubIOgeZNqdmdiQXOtUJl{NVS7cj3MfZMhMGWyc3nsc44u[WOndInsLU1CVUNiYYOgd5Vje3S{YYTlJIFnfGW{IEOgeI8hOjRiaILzJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NF0yNjZ5zszN	NGPudFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVAyQCd-MkSwPVUxOTh:L3G+
SNU16	MkL3R5l1d3SxeHnjbZR6KGG\|c3H5		M17RXVczKGi{cx?=		M{jDW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPXTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zNENOwG0>	NIjaXJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
High5	MXzGeY5kfGmxbjDhd5NigQ>?		NFnueZczPCCqcoO=		MlnQTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKRFHDNkBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IFjp[4g2KGOnbHzzJJV{cW6pIFHjMWx6ey2WeYKtUJl{KCincIPpcI9vNWGlZYT5cEkuSU2FIHHzJJN2[nO2cnH0[UBi\nSncjCyOEBpenNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyPUCuNVfPxE1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
High5	MoL3SpVv[3Srb36gZZN{[Xl?		NYiycGFXOyCqcoO=		M3TkcmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSFTBR\|Mh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDIbYdpPSClZXzsd{B2e2mwZzDBZ{1NgXNvVInyMWx6eyBqZYDzbYxwdi2jY3X0fYwqNUGPQzDhd{B{fWK\|dILheIUh[W[2ZYKgN{BpenNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyPUCuN\|bPxE1?	M{LCWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC1OFQ3Lz5{NUiwOVQ1PjxxYU6=
High5	NGPCb5pHfW6ldHnvckBie3OjeR?=		M{jsfFI1KGi{cx?=		MXjJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEiGQVOxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiSHnnbFUh[2WubIOgeZNqdmdiQXOtUJl{NVS7cj3MfZMhMGWyc3nsc44u[WOndInsLU1CVUNiYYOgd5Vje3S{YYTlJIFnfGW{IEK0JIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTB;MD6zPe69VQ>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
HCT116	MmXxR5l1d3SxeHnjbZR6KGG\|c3H5		MV:3NkBpenN?		NGryXFNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkO5Ou69VQ>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
SW620	NH3UfoxEgXSxdH;4bYNqfHliYYPzZZk>		MmrEO\|IhcHK\|		MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW\|YzOCClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvPDF7zszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
MKN45	M{HpdWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFLDTYQ4OiCqcoO=		MoPVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWtPPDViY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjZzzszN	NXXaTlV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
Hep3B	NXPDflJkS3m2b4TvfIlkcXS7IHHzd4F6		NYDObmhrPzJiaILz		MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZA{SiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvQDJ\|zszN	NFS2fo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
HepG2	NHOzbGdEgXSxdH;4bYNqfHliYYPzZZk>		MVy3NkBpenN?		M1HXe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC56N{dOwG0>	MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
SNU5	NGnMT2lEgXSxdH;4bYNqfHliYYPzZZk>		M{fLelczKGi{cx?=		MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUnU2KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU4xODoQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
A549	M2\TbmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MV:3NkBpenN?		MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9Nk4xQM7:TR?=	MkHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
SJSA1	M1j5Z2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NHzQbGw4OiCqcoO=		MoLmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2pUSTFiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0{NjZ{NN88US=>	MojDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
MHCC97H	NXLHSFN[S3m2b4TvfIlkcXS7IHHzd4F6		NV3LXGpkPzJiaILz		NIDsSINEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOUEOFOUfIJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;ND61OlPPxE1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
PANC1	MkDYR5l1d3SxeHnjbZR6KGG\|c3H5		M4nP[\|czKGi{cx?=		MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRW5EOSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI3Njd5NN88US=>	NFTZWXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
U937	NFLTTXNHfW6ldHnvckBie3OjeR?=	MYexNEB2VQ>?	MVOyOEBpenN?		NGLT[VBKdmirYnn0bY9vKG:oIFjERWM{KGmwIHj1cYFvKFV7M{egZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUuQSCjY3X0fYxifGmxbjDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=>	NGHvNlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4O\|MyOCd-Mk[yPFc{OTB:L3G+
PC3	M2HESWZ2dmO2aX;uJIF{e2G7	NInBVGgyOCC3TR?=	NEXPWXgzPCCqcoO=		MULJcohq[mm2aX;uJI9nKEiGQVOzJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIx6e2mwZT25JIFk\XS7bHH0bY9vKGG2IEGwJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfHSrbnegcYV1cG:m	NYnPUIVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPFc{OTBpPkK2Nlg4OzFyPD;hQi=>
U937	Ml7BSpVv[3Srb36gZZN{[Xl?	MWWxNEB2VQ>?	M371b\|I1KGi{cx?=		MlmyTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJHU6OzdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJIN6[2yrbjDFJIV5eHKnc4Ppc44hcW5iYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2dHnu[{Bu\XSqb3S=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6N{OxNEc,OjZ{OEezNVA9N2F-
Sf9	NVS1e3VUTnWwY4Tpc44h[XO\|YYm=		M{HaSFExKG2rboO=		MYXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IH\1cIwhdGWwZ4ToJIh2dWGwIFOteIVzdWmwYXygSmxCTy22YXfn[YQhUESDQ{GxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lkh[2WubIOgeZNqdmdiQn;jMWx6eyincIPpcI9vNUGlKT3BUWMh[XNic4Xid5Rz[XSnIIDy[ZRz\WG2ZXSg[o9zKDFyIH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIHL5JIZtfW:{b33leJJq[yCvZYToc4QtKEmFNUC9NE42Qc7:TR?=	NYfEN4xwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFE2OTRpPkK4OVAyPTF2PD;hQi=>
TC32	MYXxTHRUKGG\|c3H5				M4XPUJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	M4XnXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	M3;qfJFJXFNiYYPzZZk>				M2jlcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	NHr3cpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NFnRW3hyUFSVIHHzd4F6				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NY\OVXVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	NUO0SnZ{eUiWUzDhd5NigQ>?				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MXXxTHRUKGG\|c3H5				MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NGLKPJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NHTKdnFyUFSVIHHzd4F6				M{XKcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NHTvWGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M1zHXZFJXFNiYYPzZZk>				NI\WVY9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	NYLZS4tveUiWUzDhd5NigQ>?				MmTidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	M2DxZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	M2fLXpFJXFNiYYPzZZk>				NHnocllyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NYX2eFZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NUPpS4hneUiWUzDhd5NigQ>?				MnrzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MlLqdWhVWyCjc4PhfS=>				NVjzPZA5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NX31RWhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	NIjLU2VyUFSVIHHzd4F6				M1nVZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	MkDidWhVWyCjc4PhfS=>				M{LEXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	MmnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	NEfTbYhyUFSVIHHzd4F6				NWO2[5ZYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NWfyVHp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	M{\KWZFJXFNiYYPzZZk>				M1j0PJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MkfvdWhVWyCjc4PhfS=>				M2fyZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	NIr6[G09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MUfxTHRUKGG\|c3H5				NVX4Rmc4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	NGXnNWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
fibroblast cells	NV\zZmp2eUiWUzDhd5NigQ>?				NH3lVGVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiY3;ueJJwdCCKaDD3bYxlKHS7cHWg[oljem:kbHHzeEBk\Wyucx?=	NXfNW\|dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	M{LKPJFJXFNiYYPzZZk>				MnnWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	M{HBeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MYTxTHRUKGG\|c3H5				MnPWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	M1O1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	NH3Kb2dyUFSVIHHzd4F6				NXP3PY8yeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MkHydWhVWyCjc4PhfS=>				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	MYPxTHRUKGG\|c3H5				NFThRotyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	NWHIOZp5eUiWUzDhd5NigQ>?				NHLuTo9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	NXr0[WoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	M4nRN5FJXFNiYYPzZZk>				MonCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	Mmf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	Ml;SdWhVWyCjc4PhfS=>				Ml\ydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	NXPLVmQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Sf9	MofRSpVv[3Srb36gZZN{[Xl?				NWLsVI9IUW6qaXLpeIlwdiCDc4PhfVohUESDQzDpcohq[mm2aX;uJIF{e2G7czD3[ZJmKHCncn\vdo1m\CCkeTDS[YFkfGmxbjDCbY9td2e7IFPvdpAvKCiPYXz2[ZJvNCCSYT6pJJV{cW6pIHnzc4xifGWmIHj1cYFvNCC{ZXPvcYJqdmGwdDDmeYxtNWynbnf0bEBJTEGFMTDhcoQhNTZiZoLvcUBiKGKjY4Xsc5ZqenW\|IHX4dJJme3Orb36gd5l{fGWvIHnuJHNnQSClZXzsd{whUUN3ME2wMlExOs7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
HCT116	M{jiO2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mn3GOFghcHK\|		M1rpRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvOjUQvF2=	MlXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
MCF7	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHLWSVg4OiCqcoO=		Mmn3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUKuOFnPxE1?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
HeLa	Ml3mRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MV20PEBpenN?		M{izXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2zMlMz\|ryP	NWLy[3RERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?
HeLa	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MoTiO\|IhcHK\|		NHf5do1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9N{41Os7:TR?=	MkHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
HCT116	Mm\ORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWDmSJdDPzJiaILz		NFqzbHpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0{NjVzzszN	NHPHO209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HepG2	NYfIZ4RWSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmHLOFghcHK\|		M{LVW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OE4xPc7:TR?=	M3nHR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
HepG2	NITX[XhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYK3NkBpenN?		NX7VeWtKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01NjJ3zszN	MorVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
HepG2	Mn7xRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mme3NlQhcHK\|		M3n6bWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU44Qc7:TR?=	Mm[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
A549	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MoLSO\|IhcHK\|		MkTORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUGxMlg4\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
A549	NH\TSXJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIWwfoI1QCCqcoO=		M4XrcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2xOE42P87:TR?=	NFvweWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HCT116	NInzTIxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH\Ud2szPCCqcoO=		NUHsVIRHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OjlwNkpOwG0>	Ml7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
HeLa	MoL3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MknlNlQhcHK\|		NVG2N4xGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQ{NjkQvF2=	NFjlTGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; PubMed: 27551526 Cell Death Discov (a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies. Ac-H3 / Ac-H4 / Ac-tubulin ; PubMed: 29186204 PLoS One Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression.	27551526 29186204
Immunofluorescence	E-cadherin / ZEB1 ; PubMed: 25872941 EMBO Mol Med Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm. Nanog / MHC ; PubMed: 26240433 Stem Cells Transl Med c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm.	25872941 26240433
Growth inhibition assay	Cell viability; PubMed: 26378038 Oncotarget B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software.	26378038

In vivo

MGCD0103 significantly inhibites growth of human tumor xenografts in nude mice and the antitumor activity correlated with induction of histone acetylation in tumors. P.O. administration of MGCD0103 (2HBr salt) significantly decreases growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. MGCD0103 (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blockes growth of tumors compared with vehicle treatment alone with no change in body weight. In addition, MGCD0103 does not reduce WBC counts and is well tolerated. MGCD0103 is also orally active in many other human tumor xenograft models including NSCLC H1437. MGCD0103 at 80 mg/kg (free base) almost completely blocks the growth of H1437 tumors after 13 days of daily p.o. administration with no reduction of body weight in animals. ^[1] MGCD0103 reduces pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. Moreover, MGCD0103 improves pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse HDAC enzyme assay in vitro: The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl₂, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
Cell Research:^[1]	- Collapse Cell lines: Human mammary epithelial cells (HMEC), human foreskin fibroblasts (MRHF) cells Concentrations: 0-60 μM Incubation Time: 72 hours Method: Human mammary epithelial cells (HMEC) and human foreskin fibroblasts (MRHF) cells in 96-well plates are incubated with MGCD0103 at various concentrations for 72 hours at 37 °C in 5% CO₂. MTT is added at a final concentration of 0.5 mg/ml and incubated with the cells for 4 hours before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] is added. After overnight incubation, solubilized dye is quantified by reading at 570 nm using a reference at 630 nm. Absorbance values are converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduces cell numbers to 50% relative to DMSO-treated cells is determined as MTT IC5 (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female CD-1 nude mice bearing H1437 tumors Dosages: 80 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL (32.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% Propylene glycol For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Mocetinostat (MGCD0103) SDF

Molecular Weight	396.44
Formula	C₂₃H₂₀N₆O
CAS No.	726169-73-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	MG0103
Smiles	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04299113	Recruiting	Drug: Vinorelbine\|Drug: Mocetinostat	Rhabdomyosarcoma	Jonsson Comprehensive Cancer Center\|Mirati Therapeutics Inc.\|Phase One Foundation	May 14 2020	Phase 1
NCT02993991	Withdrawn	Drug: Mocetinostat\|Biological: Durvalumab	Squamous Cell Carcinoma Head And Neck\|Squamous Cell Carcinoma Mouth\|Resectable Squamous Cell Carcinoma of Oral Cavity	University Health Network Toronto\|Mirati Therapeutics Inc.\|AstraZeneca	October 10 2017	Phase 1
NCT02236195	Completed	Drug: Mocetinostat	Urothelial Carcinoma	Mirati Therapeutics Inc.	October 2014	Phase 2
NCT00666497	Terminated	Drug: Azacitidine\|Drug: MGCD0103	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	Mirati Therapeutics Inc.	June 2008	Phase 2
NCT00511576	Terminated	Drug: MGCD0103 & Docetaxel	Breast Cancer\|Lung Cancer\|Pulmonary Cancer\|Non-Small-Cell Lung Carcinoma\|Prostate Cancer\|Prostatic Cancer\|Gastric Cancer\|Stomach Cancer	Mirati Therapeutics Inc.	August 2007	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitors

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

Mocetinostat (MGCD0103)